Trasplante de células madre hematopoyéticas

Inicio
Noticias
Trasplante de células madre hematopoyéticas

Comunicate con el proveedor:

Contactar

!noticia guardada!

Burt RK; Deeg,HJ, Lothian ST, Santos GW. Bone Marrow Transplantation. Chapman&Hall. 2002

Bensiger W, Singer J, Appelbaum FR, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant human granulocute stimulating factor. Blood 81:3158, 1993.

Nash Richard. Hematopoietic Stem Cell Transplantation in Wintrobe’s Clinical Hematology 10th ed 875, 1999.

Sullivan KM. Graft vs. host disease. Em: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas’ Hematopoietic Cell Transplantation. 3a ed. Malden, MA: Blackwell Publishing;635- 664;2004.

K.M. Sullivan, E. Agura e C. Anasetti et al.Chronic graftversus- host disease and other late complications of boné marrow transplantation, Seminars in hematology 28 : 250-259;1991.

Weisdorf DJ, Nelson G et al., Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Chronic Leukemia Working Committee, Biol Blood Marrow Transplant. 11 :1475-8;2009.

Schmitz N, Eapen M et al., Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation, International Bone Marrow Transplant Registry; European Group for Blood and Marrow Transplantation.Blood. 108:4288-90;2006.

Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS.Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life.. Biol Blood Marrow Transplant. Feb 18. 2011.

Kerbauy FR, Rodrigues M, de Souza Santos FP, Sobrinho JN, Kutner JM, Torres MA, Ribeiro AA, de Lima M, Hamerschlak NAllogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.. Leuk Lymphoma. Feb;52(2):321-4.2011.

Golmia R, Bello I, Marra A, Hamerschlak N, Osawa A, Scheinberg MAspergillus fumigatus Joint Infection: A Review.. Semin Arthritis Rheum. Jun;40(6):580-4.2011.

Santos FP, Rodrigues M, Mac-Donald Bley do Nascimento C, Kerbauy FR, Ribeiro AA, Mauro Kutner J, Hamerschlak N.Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.. Cytotherapy;12(1):113-5. 2010.

Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F, Barros GM, Madeira MI, Simões BP, Barreira AA, Brum DG, Ribeiro AA, Kutner JM, Tylberi CP, Porto PP, Santana CL, Neto JZ, Barros JC, Paes AT, Burt RK, Oliveira EA, Mastropietro AP, Santos AC, Voltarelli JCBrazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and C.Y/ rabbit ATG..Bone Marrow Transplant.Feb;45(2):239-48. 2010.